Her2 Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
ELVN | B | Enliven Therapeutics, Inc. | 0.13 | |
GTHX | B | G1 Therapeutics, Inc. | -0.30 | |
ZYME | D | Zymeworks Inc. | 0.59 | |
GLSI | D | Greenwich LifeSciences, Inc. | 10.59 | |
PBYI | D | Puma Biotechnology Inc | 1.05 | |
OLMA | F | Olema Pharmaceuticals, Inc. | 0.62 | |
MRKR | F | Marker Therapeutics, Inc. | -3.49 | |
ZNTL | F | Zentalis Pharmaceuticals, Inc. | -0.75 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
CNCR | D | Loncar Cancer Immunotherapy ETF | 3.84 | |
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 1.23 | |
LABD | D | Direxion Daily S&P Biotech Bear 3X Shares | 1.07 | |
SBIO | D | ALPS Medical Breakthroughs ETF | 0.89 | |
XBI | D | SPDR S&P Biotech ETF | 0.71 |
Compare ETFs
- Her2
Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human), is a protein that in humans is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene isolated from avian genome. It is also frequently called HER2 (from human epidermal growth factor receptor 2) or HER2/neu.HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.
Popular Now
Recent Comments
- ZealousTrout235 on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
- TraderMike on Market Recap for Tuesday, May 21, 2024
- CharmingMole371 on Market Recap for Tuesday, May 21, 2024
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
From the Blog
Featured Articles